Dr Reddy's Laboratories EBITDA Margin 2012-2025 | RDY
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Dr Reddy's Laboratories (RDY) over the last 10 years. The current EBITDA margin for Dr Reddy's Laboratories as of December 31, 2025 is .
| Dr Reddy's Laboratories EBITDA Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM EBITDA | EBITDA Margin |
| 2025-12-31 | $3.94B | $0.98B | 24.97% |
| 2025-09-30 | $3.95B | $1.04B | 26.41% |
| 2025-06-30 | $3.89B | $1.04B | 26.81% |
| 2025-03-31 | $3.81B | $1.04B | 27.34% |
| 2024-12-31 | $3.70B | $1.01B | 27.33% |
| 2024-09-30 | $3.58B | $0.99B | 27.63% |
| 2024-06-30 | $3.45B | $0.99B | 28.78% |
| 2024-03-31 | $3.35B | $0.99B | 29.55% |
| 2023-12-31 | $3.23B | $0.95B | 29.38% |
| 2023-09-30 | $3.19B | $0.94B | 29.31% |
| 2023-06-30 | $3.15B | $0.91B | 28.99% |
| 2023-03-31 | $2.99B | $0.85B | 28.38% |
| 2022-12-31 | $2.95B | $0.72B | 24.38% |
| 2022-09-30 | $2.83B | $0.64B | 22.72% |
| 2022-06-30 | $2.82B | $0.61B | 21.57% |
| 2022-03-31 | $2.83B | $0.55B | 19.29% |
| 2021-12-31 | $2.83B | $0.65B | 22.84% |
| 2021-09-30 | $2.79B | $0.64B | 22.92% |
| 2021-06-30 | $2.67B | $0.60B | 22.58% |
| 2021-03-31 | $2.59B | $0.62B | 24.06% |
| 2020-12-31 | $2.38B | $0.62B | 26.02% |
| 2020-09-30 | $2.32B | $0.61B | 26.14% |
| 2020-06-30 | $2.34B | $0.59B | 25.14% |
| 2020-03-31 | $2.32B | $0.60B | 25.91% |
| 2019-12-31 | $2.46B | $0.58B | 23.68% |
| 2019-09-30 | $2.38B | $0.57B | 23.83% |
| 2019-06-30 | $2.24B | $0.53B | 23.53% |
| 2019-03-31 | $2.23B | $0.48B | 21.48% |
| 2018-12-31 | $2.15B | $0.44B | 20.27% |
| 2018-09-30 | $2.20B | $0.43B | 19.63% |
| 2018-06-30 | $2.21B | $0.43B | 19.27% |
| 2018-03-31 | $2.18B | $0.36B | 16.64% |
| 2017-12-31 | $2.26B | $0.38B | 16.96% |
| 2017-09-30 | $2.22B | $0.38B | 17.30% |
| 2017-06-30 | $2.21B | $0.37B | 16.96% |
| 2017-03-31 | $2.17B | $0.38B | 17.60% |
| 2016-12-31 | $2.09B | $0.39B | 18.66% |
| 2016-09-30 | $2.15B | $0.42B | 19.42% |
| 2016-06-30 | $2.22B | $0.50B | 22.58% |
| 2016-03-31 | $2.34B | $0.60B | 25.78% |
| 2015-12-31 | $2.43B | $0.66B | 27.09% |
| 2015-09-30 | $2.44B | $0.65B | 26.72% |
| 2015-06-30 | $2.40B | $0.59B | 24.66% |
| 2015-03-31 | $2.40B | $0.57B | 23.79% |
| 2014-12-31 | $2.36B | $0.52B | 22.25% |
| 2014-09-30 | $2.32B | $0.54B | 23.19% |
| 2014-06-30 | $2.27B | $0.56B | 24.67% |
| 2014-03-31 | $2.17B | $0.52B | 23.82% |
| 2013-12-31 | $2.20B | $0.52B | 23.65% |
| 2013-09-30 | $2.15B | $0.46B | 21.40% |
| 2013-06-30 | $2.16B | $0.46B | 21.19% |
| 2013-03-31 | $2.14B | $0.46B | 21.54% |
| 2012-12-31 | $2.05B | $0.53B | 25.72% |
| 2012-09-30 | $2.05B | $0.59B | 28.85% |
| 2012-06-30 | $1.96B | $0.52B | 26.24% |
| 2012-03-31 | $1.95B | $0.52B | 26.46% |
| 2011-12-31 | $1.88B | $0.39B | 20.52% |
| 2011-09-30 | $1.78B | $0.31B | 17.39% |
| 2011-06-30 | $1.74B | $0.35B | 20.33% |
| 2011-03-31 | $1.66B | $0.33B | 20.12% |
| 2010-12-31 | $1.57B | $0.28B | 17.75% |
| 2010-09-30 | $1.52B | $0.27B | 17.82% |
| 2010-06-30 | $1.48B | $0.24B | 15.85% |
| 2010-03-31 | $1.50B | $0.25B | 16.92% |
| 2009-12-31 | $1.53B | $0.45B | 29.49% |
| 2009-09-30 | $1.53B | $0.48B | 31.14% |
| 2009-06-30 | $1.50B | $0.44B | 29.51% |
| 2009-03-31 | $1.47B | $0.40B | 27.40% |
| 2008-12-31 | $1.41B | $0.25B | 17.54% |
| 2008-09-30 | $1.34B | $0.19B | 14.23% |
| 2008-06-30 | $1.31B | $0.21B | 15.99% |
| 2008-03-31 | $1.26B | $0.22B | 17.47% |
| 2007-12-31 | $1.35B | $0.32B | 23.46% |
| 2007-09-30 | $2.16B | $1.11B | 51.46% |
| 2007-06-30 | $2.58B | $1.45B | 56.36% |
| 2007-03-31 | $2.59B | $1.45B | 55.83% |
| 2006-12-31 | $1.94B | $1.27B | 65.57% |
| 2006-09-30 | $0.95B | $0.22B | 22.63% |
| 2006-06-30 | $0.34B | $-0.28B | -82.94% |
| 2006-03-31 | $0.16B | $-0.32B | -198.15% |
| 2005-12-31 | $0.49B | $-0.32B | -65.15% |
| 2005-09-30 | $0.47B | $0.55B | 115.61% |
| 2005-06-30 | $0.46B | $0.66B | 143.91% |
| 2005-03-31 | $0.44B | $0.66B | 148.87% |
| 2004-12-31 | $0.46B | $0.67B | 145.41% |
| 2004-09-30 | $0.45B | $0.53B | 117.04% |
| 2004-06-30 | $0.45B | $0.53B | 118.40% |
| 2004-03-31 | $0.44B | $0.54B | 122.35% |
| 2003-12-31 | $0.43B | $0.35B | 81.73% |
| 2003-09-30 | $0.41B | $0.25B | 61.48% |
| 2003-06-30 | $0.40B | $0.25B | 64.14% |
| 2003-03-31 | $0.39B | $0.26B | 67.79% |
| 2002-12-31 | $-1.98B | $0.27B | -13.71% |
| 2002-09-30 | $-1.97B | $-0.10B | 5.17% |
| 2002-06-30 | $-1.97B | $-0.09B | 4.41% |
| 2002-03-31 | $0.34B | $0.12B | 35.00% |
| 2001-12-31 | $2.82B | $0.37B | 13.00% |
| 2001-09-30 | $2.84B | $0.35B | 12.24% |
| 2001-06-30 | $2.84B | $0.32B | 11.31% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $11.806B | $3.811B |
| Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments: Global Generics comprising unbranded prescription drugs along with over-the-counter drugs. It includes the operations of the company's biologics business. Pharmaceutical Services & Active Ingredients (PSAI) comprising active pharmaceutical ingredients (API) and custom pharmaceutical services. Proprietary Products and Others involving the new chemical entities, the differentiated formulations business and a dermatology specialty business. The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $39.071B | 12.09 |
| BridgeBio Pharma (BBIO) | United States | $14.501B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.915B | 23.87 |
| Bausch Health Cos (BHC) | Canada | $2.222B | 1.58 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.310B | 9.44 |
| Taysha Gene Therapies (TSHA) | United States | $1.246B | 0.00 |
| Personalis (PSNL) | United States | $0.729B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.422B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.187B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.055B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |